Expand CLRB Menu
CLRB MENU

CLRB Latest Press Releases

-- June 1, 2026 --

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstrm Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting Globe Newswire 8:05 AM

-- May 14, 2026 --

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:15 AM

-- May 11, 2026 --

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 Globe Newswire 8:05 AM

-- May 5, 2026 --

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenstrm Macroglobulinemia Globe Newswire 7:10 AM
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million Globe Newswire 7:00 AM

-- April 21, 2026 --

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 Globe Newswire 10:00 AM

-- April 14, 2026 --

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) Globe Newswire 8:35 AM

-- March 4, 2026 --

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates Globe Newswire 7:15 AM

-- February 25, 2026 --

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 Globe Newswire 8:05 AM

-- February 17, 2026 --

Cellectar Biosciences Expands Global Intellectual Property Estate Globe Newswire 8:05 AM
Market Data Delayed 15 Minutes